Patents by Inventor Charles Eric Mowbray
Charles Eric Mowbray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11691992Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.Type: GrantFiled: February 11, 2021Date of Patent: July 4, 2023Assignees: Anacor Pharmaceuticals, Inc., The Government of the United States, as represented by the Secretary of the ArmyInventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
-
Publication number: 20210253605Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.Type: ApplicationFiled: February 11, 2021Publication date: August 19, 2021Inventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
-
Patent number: 10961261Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.Type: GrantFiled: March 1, 2018Date of Patent: March 30, 2021Assignees: Anacor Pharmaceuticals, Inc., The Government of the United States, as represented by the Secretaryof the ArmyInventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
-
Publication number: 20200024289Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.Type: ApplicationFiled: March 1, 2018Publication date: January 23, 2020Applicants: Anacor Pharmaceuticals, Inc., The Government of the United States, as represented by the Secretary of the Army, The Government of the United States, as represented by the Secretary of the ArmyInventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
-
Publication number: 20120029192Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivatives thereof, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such, the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).Type: ApplicationFiled: October 7, 2011Publication date: February 2, 2012Inventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
-
Patent number: 8063044Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereofs, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).Type: GrantFiled: August 25, 2008Date of Patent: November 22, 2011Assignee: Pfizer Inc.Inventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
-
Patent number: 7943628Abstract: A compound of Formula (I): or a pharmaceutically and/or veterinarily acceptable derivative thereof, wherein R1, R2, R3, R4, R5, and R8 are as defined above.Type: GrantFiled: December 15, 2006Date of Patent: May 17, 2011Assignee: Pfizer LimitedInventors: Andrew Simon Bell, Charlotte Alice Louise Lane, Charles Eric Mowbray
-
Publication number: 20090264425Abstract: This invention relates to biaryl ether derivatives of formula (I) wherein R1, R3, R4, X, W, Y and m are defined in the description, and to compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof.Type: ApplicationFiled: December 12, 2005Publication date: October 22, 2009Inventors: Lyn Howard Jones, Donald Stuart Middleton, Charles Eric Mowbray, Sandra Dora Newman, David Howard Williams
-
Publication number: 20090215712Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereofs, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).Type: ApplicationFiled: August 25, 2008Publication date: August 27, 2009Inventors: Lyn Howard JONES, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
-
Patent number: 7435728Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereofs, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).Type: GrantFiled: June 20, 2005Date of Patent: October 14, 2008Assignee: Pfizer IncInventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
-
Publication number: 20080132549Abstract: This invention relates to isophthalonitrile derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1 to R3 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof.Type: ApplicationFiled: April 11, 2005Publication date: June 5, 2008Applicant: Pfizer Inc.Inventors: Lyn Howard Jones, Shahid Mohammed, Sandra Newman, Charles Eric Mowbray, Matthew Ducan Selby, Paul Anthony Stupple, Nigel Alan Swain
-
Patent number: 7220772Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).Type: GrantFiled: September 5, 2003Date of Patent: May 22, 2007Assignee: Pfizer, Inc.Inventors: Paul John Edwards, Lyn Howard Jones, Charles Eric Mowbray, Paul Anthony Stupple, Isabelle Tran
-
Patent number: 7157468Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1 to R4, n W, X and Y are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).Type: GrantFiled: September 23, 2003Date of Patent: January 2, 2007Assignee: Pfizer Inc.Inventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
-
Patent number: 7141585Abstract: This invention relates to the use of pyrazole derivatives of the formula and pharmaceutically acceptable salts and solvates thereof, in the manufacture of a reverse transcriptase inhibitor or modulator, to certain novel such pyrazole derivatives and to processes for the preparation of and compositions containing such novel derivatives.Type: GrantFiled: April 26, 2004Date of Patent: November 28, 2006Assignee: Agouron Pharmaceuticals, Inc.Inventors: Romuald Gaston Corbau, Charles Eric Mowbray, Manoussos Perros, Paul Anthony Stupple, Anthony Wood
-
Patent number: 7109228Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivatives thereof, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such, the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).Type: GrantFiled: April 5, 2002Date of Patent: September 19, 2006Assignee: Agouron Pharmaceuticals, Inc.Inventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
-
Publication number: 20040209862Abstract: This invention relates to the use of pyrazole derivatives of the formula 1Type: ApplicationFiled: April 26, 2004Publication date: October 21, 2004Applicant: PFIZER, INC.Inventors: Romuald Gaston Corbau, Charles Eric Mowbray, Manoussos Perros, Paul Anthony Stupple, Anthony Wood
-
Publication number: 20040132793Abstract: This invention relates to the pyrazole derivatives of formula (I) 1Type: ApplicationFiled: September 12, 2003Publication date: July 8, 2004Applicant: Pfizer Inc.Inventors: Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
-
Patent number: 6750230Abstract: This invention relates to the use of pyrazole derivatives of the formula and pharmaceutically acceptable salts and solvates thereof, in the manufacture of a reverse transcriptase inhibitor or modulator, to certain novel such pyrazole derivatives and to processes for the preparation of and compositions containing such novel derivatives.Type: GrantFiled: July 5, 2001Date of Patent: June 15, 2004Assignee: Pfizer, Inc.Inventors: Romuald Gaston Corbau, Charles Eric Mowbray, Manoussos Perros, Paul Anthony Stupple, Anthony Wood
-
Publication number: 20030100554Abstract: This invention relates to pyrazole derivatives of formula (I) 1Type: ApplicationFiled: April 5, 2002Publication date: May 29, 2003Inventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
-
Patent number: 6376490Abstract: The invention provides compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein R is a 5-membered ring heteroaryl group containing 3 or 4 nitrogen heteroatoms which is linked to the quinoxalinedione ring by a ring carbon or nitrogen atom said group being optionally benzo-fused and optionally substituted, including in the benzo-fused portion, by 1 or 2 substituents each independently selected from C1-C4 alkyl, C2-C4 alkenyl, C3-C7 cycloalkyl, halo, hydroxy, C1-C4 alkoxy, C3-C7 cycloalkyloxy, —COOH, C1-C4 alkoxycarbonyl, —CONR3R4, —NR3R4, —S(O)p(C1-C4 alkyl), —SO2NR3R4, aryl, aryloxy, aryl(C1-C4)alkoxy, and het, said C1-C4alkyl being optionally substituted by C3-C7 cycloalkyl, halo, hydroxy, C1-C4 alkoxy, halo(C1C4)alkoxy, C3-C7 cycloalkyloxy, C3-C7 cycloalkyl (C1-C4) alkoxy, —COOH, C1-C4 alkoxycarbonyl, —CONR3R4, —NR3R4,—S(O)p(C1-C4 alkyl), —SO2(aryl), —SO2NR3R4 morpholino, aryl, aryloxy, aryl(C1-C4)Type: GrantFiled: September 4, 1998Date of Patent: April 23, 2002Assignee: Pfizer IncInventors: David John Bull, Christopher Lee Carr, Michael Jonathan Fray, Elisabeth Colette Louise Gautier, Charles Eric Mowbray, Alan Stobie